Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 23

All patients

Hormone Receptor

negative

Hormone Receptor

positive

PFS

Hazard Ratio

0.62

0.55

0.72

Hazard Ratio

0.68

0.61

0.71

CLEOPATRA:

Pertuzumab is efficacious in hormone receptor positive

and negative subgroups

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,13,14,15,16,17,18,19,20,21,22 24,25,26,27,28,29,30,31,32,33,...47